Pneumococcal vaccine protein-based - sanofi pasteur

Drug Profile

Pneumococcal vaccine protein-based - sanofi pasteur

Alternative Names: Pneumococcal vaccine - Provalis/sanofi pasteur

Latest Information Update: 09 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Provalis
  • Developer Sanofi Pasteur
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pneumococcal infections

Most Recent Events

  • 08 Jan 2013 Protein-based pneumococcal vaccine is still in phase I trials for Pneumococcal infections in Bangladesh
  • 30 Sep 2011 Phase-I clinical trials in Pneumococcal infections in Bangladesh (Parenteral)
  • 13 Dec 2004 Preclinical trials in Pneumococcal infections in France (Parenteral )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top